NCT00192465View on ClinicalTrials.gov

Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

April 30, 2004

Study Completion Date

November 30, 2004

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

MEDI-524 (Numax-TM)

Grp.1: 3 mg/kg IV (single dose)

BIOLOGICAL

MEDI-524 (Numax-TM)

Grp. 2: 15 mg/kg IV (single dose)

BIOLOGICAL

MEDI-524 (Numax-TM)

Grp. 3: 30 mg/kg IV (single dose)

BIOLOGICAL

MEDI-524 (Numax-TM)

Grp. 4: 3 mg/kg IM (single dose)

BIOLOGICAL

MEDI-524 (Numax-TM)

Grp.5: 3 mg/kg IM (two doses)

Trial Locations (1)

33181

SFBC International, Inc, Miami

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT00192465 - Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults | Biotech Hunter | Biotech Hunter